16 Sep 2026 Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial Investors | Therapeutics
14 Sep 2026 Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee Investors